secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2026-10-23T21:00:48+00:00
Accession:  0001193125-26-430621
Event type: litigation
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BDR sues FDA over VOQUEZNA NCE exclusivity; Phathom defends 10-year term to May 2032
--------------------------------------------------------------------------------

- BDR Pharmaceuticals International Pvt. Ltd. sued FDA and related Federal Defendants in the U.S. District Court for the District of Columbia over an ANDA referencing Phathom's VOQUEZNA NDA.
- BDR alleges FDA improperly applied the GAIN Act to extend Phathom's New Chemical Entity exclusivity for VOQUEZNA (vonoprazan fumarate) tablets.
- Phathom says FDA correctly recognized 10 years of NCE exclusivity through May 3, 2032 in its June 6, 2025 grant of Phathom's December 11, 2024 Citizen Petition.
- Phathom intends to take appropriate action to protect its statutory exclusivities; it warns an adverse outcome could shorten exclusivity and allow ANDAs earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526430621/0001193125-26-430621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312526430621/d437998d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-430621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer